% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Abba:119310,
      author       = {M. L. Abba and N. S. Patil$^*$ and J. H. Leupold and M.
                      Moniuszko and J. Utikal$^*$ and J. Niklinski and H.
                      Allgayer$^*$},
      title        = {{M}icro{RNA}s as novel targets and tools in cancer
                      therapy.},
      journal      = {Cancer letters},
      volume       = {28},
      number       = {387},
      issn         = {0304-3835},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2017-00065},
      pages        = {84 - 94},
      year         = {2017},
      abstract     = {MicroRNAs (miRNAs) are currently experiencing a renewed
                      peak of attention not only as diagnostics but also
                      especially as highly promising novel targets or tools for
                      clinical therapy in several different malignant diseases.
                      Moreover, the recent discovery of competing endogenous RNAs
                      (ceRNAs) as novel miRNA-regulators has contributed exciting
                      insights in this regard. Therefore, this review summarizes
                      and discusses the latest findings on (1) how miRNAs have
                      become therapeutic targets of diverse synthetic antagonists,
                      (2) how novel endogenous regulators of miRNAs such as ceRNAs
                      or pseudogenes could emerge as therapeutics scavenging
                      oncogenic miRNAs and (3) how miRNAs themselves are already,
                      and will increasingly be, used as therapeutics. Recent
                      advances on the importance of miRNA-target affinity and the
                      subcellular localization of miRNAs are also discussed. The
                      potential of these developments in different tumor entities
                      and particular hallmarks of cancer such as metastasis,
                      disease progression, interactions with the tumor
                      microenvironment, or cancer stem cells are equally
                      highlighted.},
      subtyp        = {Review Article},
      cin          = {G360 / G300},
      ddc          = {570},
      cid          = {I:(DE-He78)G360-20160331 / I:(DE-He78)G300-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27045478},
      doi          = {10.1016/j.canlet.2016.03.043},
      url          = {https://inrepo02.dkfz.de/record/119310},
}